

SYNDROME OF BURNED SKIN IMPROVEMENTS IN TREATMENT AND DIAGNOSIS

Dr. Zeeshan Hussain¹, Ayesha Nazir², Faisal Nadeem³, khola Ahmad⁴

¹MBBS (China), RPD-FM (AKU), PGD-HM (HSA), Underwater and Hyperbaric Medicine Specialist, PNS SHIFA Hospital, DHA Phase-II, Karachi

Email: Dr.zeeshanhussain90@gmail.com

ORCID ID: <https://orcid.org/0009-0007-8302-759X>

²Pharmacist, Department of Pharmacy, Islamia University Bahawalpur, Pakistan

Email: ayeshapharmacist@hotmail.com

³MBBS, Punjab Medical College, Faisalabad, Pakistan

Email: faisal13069@gmail.com

⁴Department of Allied Health Sciences, Sargodha Medical College, University of Sargodha, Sargodha, Pakistan, Email: kholaahmed99@gmail.com

Corresponding author: Dr. Zeeshan Hussain MBBS (China), RPD-FM (AKU), PGD-HM (HSA), Underwater and Hyperbaric Medicine Specialist, PNS SHIFA Hospital, DHA Phase-II, Karachi, Email: Dr.zeeshanhussain90@gmail.com, ORCID ID: <https://orcid.org/0009-0007-8302-759X>

ABSTRACT

Background: Staphylococcus aureus produces epidermolytic toxins that disrupt epidermal cell connections, resulting in staphylococcal scalded skin syndrome (SSSS). Blisters, erythematous cellulitis, and superficial skin peeling characterize this condition.

Objective: To provide an overview of the clinical foundation, etiopathogenesis, complications, current treatment options, and potential future advancements in managing SSSS.

Methods: This review synthesizes available data on the pathogenesis, clinical manifestations, differential diagnoses, and therapeutic interventions for SSSS.

Results: It is classified as a toxin-mediated infection, primarily affecting adults and pediatric patients. Key therapeutic interventions include:

1. **Wound care** to protect damaged skin.
2. **Antibiotic therapy** with antistaphylococcal medications.
3. **Supportive care** with analgesia.

Differential diagnoses such as toxic epidermal necrolysis, adverse drug reactions, and Stevens-Johnson syndrome require multidisciplinary evaluation by dermatologists, infectious disease specialists, and surgeons.

Conclusion: Effective management of SSSS involves a multidisciplinary approach to reduce mortality. Future developments may enhance understanding and treatment outcomes for this toxin-mediated disease.

Keywords: infection with *Staphylococcus aureus*, staphylococcal scalded skin syndrome, and staphylococcal toxic shock syndrome.

INTRODUCTION:

German physicians initially reported the symptoms of staphylococcal scalded skin syndrome (SSSS) in 1878. It is associated with an acute dermatosis that manifests clinically as fever, erythema, and widespread epidermal detachments. It is brought on by the epidermolytic toxins A and B of *Staphylococcus aureus*. Only a few more than 32 species and subspecies that comprise the *Staphylococcus* genus are harmful. Despite the introduction of antibiotics, *Staphylococcus aureus* remains the most pathogenic species in the genus and is still a common cause of illness and death. It exhibits opportunistic behaviour and can cause septic metastases and abscesses, producing invasive and toxic infections, such as S (Fellows et al., 2021).

This microorganism colonizes between 30 and 55 per cent of healthy individuals, either temporarily or permanently. This percentage is even higher in insulin-dependent diabetic patients who have HIV infection, dialysis patients who are scheduled for parenteral drug addiction, and people who have chronic skin diseases. The axillae, perineum, vagina, nasal passageways, and oropharynx are the sites of colonization that occur most frequently. These locations are more common in people who have already been colonized because they serve as reservoirs for future infections. With a gender ratio of 3:1, a prevalence of 0.08 to 0.55 persons per million people is reported, with a higher frequency in newborns (acquired through the birth canal) and those under the age of 5.5. The age range for a presentation is three to four years old at most (Pereira et al., 2022).

Immunosuppression, immunoglobulin deficiency, chronic renal failure, and renal immaturity are risk factors for SSSS. However, SSSS has a substantial risk of morbidity and death if it is not promptly and well treated. Adult mortality rates as high as 65% have been documented; these deaths are most likely due to immunosuppressive conditions or major underlying illnesses. Children usually die at a rate of no more than 6% (De Seta et al., 2021).

Pathophysiology

Methicillin-resistant strains of *S. aureus* are also colonizing more frequently, leading to an increasing number of problems, including *S. aureus*. Despite this, exfoliative toxins A (ETA) and B (ETB) are only produced by 6% of *S. aureus* isolates from people. ETB is considered the more aggressive of the two atypical serum proteins comparable to trypsin and specific glutamic acid that builds up in the skin. A desmosomal cadherin implicated in keratinocyte cell adhesion, desmoglein complex 1, is cleaved due to ETA and ETB building up in the skin. Exfoliation is finally brought on by the breakdown of the desmosomes that hold the granular layers in place. Since the toxin can travel through the bloodstream to locations far from the site of the primary infection, although typically originating in the head and neck area (conjunctivitis, nasopharyngitis, otitis media), the staph that initially causes the disease is frequently not found in biopsies or cultures (Al-Niaimi et al., 2020).

Factors at risk

It is a pathology that can strike at any age. Still, as previously noted, children under the age of six are more likely to experience it than adults, with no discernible sex difference. There have also been reports of an increase in this incidence in youngsters in the summer and fall. Several explanations have been proposed to explain the higher occurrence in youngsters, two of which are the immaturity of the kidneys for the excretion of exfoliative toxins and the absence of development of protective antibodies against them. Adults with underlying diseases are primarily

at risk due to their higher mortality rates (61% and higher), immunosuppression linked to renal failure, diabetes mellitus, malignant neoplasms, chemotherapy, intravenous drug use, or human immunodeficiency virus infection (Paraiso et al., 2020).

The inability of the toxin to be excreted and the inability of the body to produce antibodies against it would be the pathogenesis linked to these risk factors. However, because of the presence of contaminated vascular accesses, the incapacity of renal excretion, and the ensuing immunological deficiency, patients undergoing hemodialysis are more susceptible to infection. A gene encoding the more virulent exotoxin ETB is present in the *S. aureus* strain linked to cases of immunocompetent persons with the illness (Paraiso et al., 2020; Tikka et al., 2020).




Figure 1: S pathophysiological processes.

Clinical image

From the time of infection to the ultimate expression of an S, the incubation period ranges from 1 to 11 days. Traditionally, the clinical picture starts with a prodrome marked by fever and general malaise, followed by an abruptly developing global erythematous rash. The patient presents with a scarlet rash on the second day, along with cutaneous hyperesthesia, bullous lesions, and a positive Nikolski sign (easy blister rupture under slight tangential pressure)

on the trunk, folds, periorificial region, and lesions' spread sites. They develop into generalized skin exfoliation between the third and fifth day, eventually leading to well-defined erythematous patches that can spread to areas more significant than the original lesions. These are typically accompanied by fever and altered consciousness. Skin stripped of its outer layer is susceptible to serous fluid leaking, which can lead to secondary infections (Keating et al., 2024).

After ten days or so, babies typically go through a second peeling period. In 16 days, the lesions completely healed with no skin aftereffects. Adults usually experience a more severe course of symptoms, but their clinical presentation is similar to that of children. There is just one documented instance of congenital S, and it usually manifests in infants between the third and seventh day of life. Unlike toxic epidermal necrolysis or Lyell's syndrome, it does not impact the mucosa. Bacteria are never discovered in the lesions, and the illness is self-limiting and lasts 5 to 9 days. Bullous impetigo may also be linked to these lesions (Dimitrov et al., 2021).

Identification

Most of the diagnosis is clinical. The manifestation of vesiculobullous lesions, a positive Nikolsky sign and the look of burned skin raise suspicions. At first, I may be mistaken for other conditions, such as toxic epidermal necrolysis, immunological drug reactions, or infections. These conditions can be clinically distinguished from SSSS by the lack of mucosal involvement, the superficial peeling of SSSS, and the lack of a prescription history. Although the yield is low, blood cultures can be used where the organism is likely to be isolated. Cultures of lesions are not advised. Since our services do not offer the exfoliative toxin gene, PCR is not required for diagnosis beyond academic purposes (Klim et al., 2020).

Difficulties

Although they are uncommon, sepsis, toxic shock syndrome, pneumonia, and dehydration are among the complications of SSSS. Fluid management and laboratory monitoring are essential because electrolyte abnormalities can result from dehydration. Prompt diagnosis and intervention halt more skin peeling and avert morbidity and death (Liu et al., 2023).




Figure 2: Histopathological depiction and biopsy of S

Handling

It necessitates a multimodal approach because histological testing can rapidly distinguish S from other comparable disorders, for which a biopsy is advised but not strictly required for diagnosis (Kamle et al., 2021).

Histopathology

The degree of excision in S is significantly more superficial than in other illnesses, such as toxic epidermal necrolysis, which is crucial for histological distinction. A ward for critically

ill or burned patients is the ideal location for hospitalization. It comprises three main pillars: analgesics, antibacterial therapy, and support (King et al., 2021).

Medium:

Patients need to be treated with wound care and fluid replenishment, just like they would for thermal burns. Electrolytes must be routinely checked, fluid loss must be made up for, hypovolemia must be avoided, and hyponatremia brought on by hypervolemization requires special attention. Covering exposed skin will help to prevent subsequent infections and promote recovery. After applying saline-soaked gauze, the denuded area should be covered with a soft silicone primary dressing. Warm air blankets should keep adults and children at rest to maintain a core temperature of 37°C. In addition, physical therapy is used to preserve joint mobility, which lowers morbidity and speeds up healing (Riyal et al., 2023).

Pain Relief:

Opioids like fentanyl (1-4 µg/kg/h) and paracetamol can be given as needed. NSAIDs should be avoided since they raise the risk of bleeding and have renal excretion. Midazolam (50–100 µg/kg/h) sedation might be helpful for younger individuals. Medication can be taken as needed to relieve itching (Khalsa et al., 2020).

Antimicrobial Treatment:

It is crucial to start antibiotic therapy as soon as possible, even if burned skin syndrome won't progress for 24 to 48 hours after it begins until the exotoxins are neutralized by antibodies or eliminated by the liver. The course of treatment involves injecting antistaphylococcal antibiotics, such as cloxacillin, intravenously for a minimum of seven days to eradicate the initial infection. It is currently thought that every staphylococcus strain has penicinyases and is

penicillin-resistant. Synthetic penicillins, such as flucloxacillin, should be given immediately, 50–150 mg/kg/day for children and 500–1000 mg/day for adults, divided into four doses. Vancomycin (45 mg/kg/day in three daily doses) should be administered to methicillin-resistant *S. aureus* where the bacteria is expected or methicillin-resistant strains are the source of infection. It is known that clindamycin can counteract exotoxin release in staphylococcal infections. If the patient has a cloxacillin allergy, cefuroxime or ciprofloxacin may be used instead (Sánchez, 2020).

ALTERNATIVE TREATMENTS:

Although no randomized clinical trials have been carried out, the use of exotoxin-neutralizing medicines, such as fresh frozen plasma and immunoglobulin, has been investigated in the case of patients who have not improved with antibiotic treatment. Here are a few of the therapy options:

- Corticosteroids: Since they have been linked to worsening the condition, corticosteroid use should be avoided.
- Immunoglobulins: Although intravenous immunoglobulins have been suggested as a treatment for S, subsequent case studies have linked these individuals to more extended hospital stays.
- Fresh frozen plasma: children in poor condition may get a dose of fresh frozen plasma (10 mg/kg) to neutralize antibodies against exfoliative toxin. 92% of adults over 41 have antibodies against exfoliative toxin.
- Laxatives: It has been proposed that administering substances like lactulose may aid in the excretion of toxins, particularly in highly young patients whose kidneys are not fully matured.

PROJECTED

Following proper therapy, most cases resolve in 2 to 3.5 weeks without any aftereffects. The mortality rate among pediatric patients is around 5%, and it is linked to refractory sepsis, severe

skin involvement, and imbalances in fluid and electrolytes. There are reports of adult fatality rates exceeding 60%, which can be attributed to underlying factors that increase an individual's susceptibility to the disease (You et al., 2023).

Differential diagnosis

Toxic shock syndrome caused by staphylococci

It relates to an uncommon side effect of an infection with *S. aureus*. Clinical symptoms include fever, rash on the skin, and shock. These can develop into multiorgan involvement, including respiratory distress, DIC, liver failure, and renal failure. It is created by the superantigen-like toxin TSST-1, which intensifies the immune response by releasing a lot of cytokines. Depending on the extent of multiorgan involvement, it might manifest as changes in laboratory tests with leukocytosis with neutrophilia, thrombocytopenia, increased prothrombin time, leukopenia, and varying degrees of biochemical profile alteration. A related investigation relates to TSST-1 gene PCR (Haion et al., 2024).

Three main components support the treatment: immunomodulators, antibiotics, and resuscitation. The first resuscitation step involves replacing crystalloids and using a central venous catheter for monitoring. Vasopressor medications (dobutamine and norepinephrine) are continued when therapy fails. After blood culture, microbiological care entails treating with antibiotics and removing any potential infection triggers. A broad-spectrum antibiotic regimen should be used, which includes clindamycin with cloxacillin or flucoxacillin to inhibit the synthesis of TSST-1 toxins. As an alternate treatment for resistant agents, studies have demonstrated the inhibitory effects of tigecycline and linezolid on synthesizing toxins. It has been shown that it is beneficial to employ immunoglobulins as immunomodulators to prevent the TSST-1 toxin's superantigenic activity (Omar & Mohammed, 2021).

Stevens-Johnson syndrome – toxic epidermal necrolysis

Both toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are related diseases that include a cutaneous hypersensitivity reaction that is typically brought on by medication. The percentage of impaired skin surface (less than 10% in SJS and more than 31% in TEN) indicates the difference between these two conditions. Although the exact pathophysiology is unknown, it is thought to be brought on by a compromised ability to excrete drug intermediate metabolites, which could then create antigenic complexes and incite an immunological response in the afflicted person. There have been several genetic susceptibilities identified. Although symptoms from *Mycoplasma pneumoniae*, herpes, HIV, and hepatitis viruses have also been reported, medicines account for the majority of cases. The three related medications that are most commonly discussed are lamotrigine, carbamazepine, and allopurinol (Ghassemi et al., 2020).

An annual incidence of 0.4 to 1.3 persons per million is reported. Any age group can experience it. However, women, those living with HIV, recipients of bone marrow transplants, the elderly, and those suffering from systemic lupus erythematosus are more likely to experience it. Prodrome symptoms, including fever, myalgias, arthralgias, and poor general conditions, typically accompany the illness's initial stages. Erythematous skin lesions, also known as targets, appear a few days later. It is noteworthy that 96% of patients with SJS/TEN have mucosal involvement, which is more common than in burned skin syndrome. Eliminating the causing factor and supportive therapy are the cornerstones of treatment. Since most of these symptoms are brought on by medications, as was previously noted, the substance thought to cause these symptoms should be stopped as soon as they manifest (Schlievert et al., 2023).

If the source is bacterial, the appropriate antibiotic therapy must be implemented. Admission to intensive care or burn unit, wound superinfection detection and treatment, electrolyte balance, and nutritional support are desirable components of supportive management. Although several immunomodulatory therapies have been reported, there is debate regarding their efficacy. We can recall corticosteroids, immunoglobulins, and cyclosporine, among others. Drug response accompanied by systemic symptoms and eosinophilia. Drug reaction with

eosinophilia and systemic symptoms (DRESS syndrome), an uncommon illness affecting the skin and internal organs, is another alternative diagnosis of SSSS. It is thought to occur once every 1,000–10,000 drug exposures. Among the medications linked to this illness are allopurinol, antibiotics, and anticonvulsants like carbamazepine (McLauchlin et al., 2000).

Not all of the pathophysiology is known. It has been proposed that there is an unusual way for drug metabolites to be detoxified by enzymes. Herpes family virus reactivation has also been linked to it. *DRESS* typically appears two to six weeks following medication use. The prodrome lasts a few days before the skin symptoms and starts with itching and fever. Although they differ, the morbilliform rash is the most typical. The traditional distribution initially affects the face, trunk, and upper limbs before moving on to the lower limbs. It could be connected to purpura, bullae, target lesions, and vesicles. As the rash worsens, exfoliative dermatitis may develop. Mucosal involvement and facial oedema are frequent. This condition affects the systems (Mehrotra et al., 2000).

The most common types are haematological (leukocytosis, eosinophilia), hepatic (elevated transaminases, alkaline phosphatase), lymphatic (adenopathies), and cardiac (respiratory, pulmonary, and cardiac). The Bouquet criterion comprises skin rash, eosinophilia, and involvement of several internal organs identified for this illness, one of three diagnostic criteria presented. The most crucial therapy action is to determine which drug is causing the problem and stop giving it. Consideration should be given to symptomatic treatment, which includes topical antipyretics and corticosteroids to reduce skin complaints. Nutritional assistance, hydroelectrolyte management, and antibiotic therapy in case of bacterial superinfection should be carried out if it develops into exfoliative dermatitis. For most patients, early systemic corticosteroid medication initiation is advised (Parsonnet et al., 2005).

CONCLUSION:

Acute dermatosis, known as S syndrome, is brought on by the toxins produced by *S. aureus*. This microbe can temporarily or permanently colonize a non-negligible percentage of the

population. Considering the preceding, one of its salient features is that it is regarded as an opportunistic illness; on the other hand, S carries a high risk of morbidity and mortality if left untreated. It has symptoms that have been reported in several publications. Still, a high level of clinical suspicion and eliminating other illnesses with comparable symptoms and signs are necessary. In addition to the previously mentioned, even though the etiopathogenic mechanisms involved have been defined, the majority of the evidence for management, given its low occurrence, comes from case reports and expert judgments.

REFERENCES:

- Al-Niaimi, F., Glagoleva, E., & Araviiskaia, E. (2020). Pulsed dye laser followed by intradermal botulinum toxin type-A in treating rosacea-associated erythema and flushing. *Dermatologic Therapy*, 33(6), e13976.
- De Seta, F., Caruso, S., Di Lorenzo, G., Romano, F., Mirandola, M., & Nappi, R. E. (2021). Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study. *Maturitas*, 147, 34-40.
- Dimitrov, E., Minkov, G., Enchev, E., & Yovtchev, Y. (2021). PROGNOSTIC PERFORMANCE OF WORLD SOCIETY OF EMERGENCY SURGERY SEPSIS SEVERITY SCORE IN BULGARIAN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS. *Trakia Journal of Sciences*, 19(3), 253.
- Fellows, J., Voegeli, D., Håkan-Bloch, J., Herschend, N. O., & Størling, Z. (2021). Multinational survey on living with an ostomy: prevalence and impact of peristomal skin complications. *British Journal of Nursing*, 30(16), S22-S30.
- Ghassemi, M. R., Doust, R. H., Haghighi, S., Akhgari, M., & Nazparvar, B. (2020). Evaluation of the toxic shock syndrome gene (TSSTI) of *Staphylococcus aureus* in deceased Neonates of Tehran Forensic Medicine Organization from October 2017 to October 2018. *Archives of Pharmacy Practice*, 1, 176.

- Haion, O., Tatz, A. J., Dahan, R., Harel, S., Sutton, G. A., & Kelmer, G. (2024). Incisional complications after skin closure with stainless-steel skin staples compared to nylon sutures in horses undergoing colic surgery. *Equine Veterinary Education*, 36(5), 245-252.
- Kamle, A., Awasthi, P., Rawat, N., Parikh, S., & Jadhav, P. (2021). Clinicopathological diagnosis of leprosy: comparative evaluation of three staining methods for acid-fast bacilli in slit skin smears and biopsy specimens. *Indian J Lepr*, 93, 15-27.
- Keating, M., Yoo, L. J. H., Lane-O'Neill, B., Moran, T., Ainle, F. N., Moloney, F. J., & Potter, S. (2024). Staphylococcus Scalded Skin Syndrome-Induced Thrombosis Leading to Free Flap Complications: A Case Report and Review. *Cureus*, 16(4).
- Khalsa, S. S. S., Hollon, T. C., Adapa, A., Urias, E., Srinivasan, S., Jairath, N., Szczepanski, J., Ouillette, P., Camelo-Piragua, S., & Orringer, D. A. (2020). Automated histologic diagnosis of CNS tumours with machine learning. *CNS oncology*, 9(2), CNS56.
- King, C., Elsherif, N., Kirwan, R., Schilling, C., Hall, G., Morgan, P., Collins, L., Sandison, A., Odell, E., & Thavaraj, S. (2021). Serial step sections at narrow intervals with immunohistochemistry are required for accurate histological assessment of sentinel lymph node biopsy in oral squamous cell carcinoma. *Head & Neck*, 43(10), 2985-2993.
- Klim, S. M., Amerstorfer, F., Bernhardt, G. A., Sadoghi, P., Hauer, G., Leitner, L., Leithner, A., & Glehr, M. (2020). Excellent mid-term osseointegration and implant survival using metaphyseal sleeves in revision total knee arthroplasty. *Knee Surgery, Sports Traumatology, Arthroscopy*, 28(12), 3843-3848.
- Liu, X., Yang, Y., & Huang, X. (2023). We are evaluating the resistance of potato cultivars to powdery scab and transcriptome analysis under the stress of *Spongospora subterranea*.
- Mclauchlin, J., Narayanan, G., Mithani, V., & O'Neill, G. (2000). The detection of enterotoxins and toxic shock syndrome toxin genes in *Staphylococcus aureus* by polymerase chain reaction. *Journal of Food Protection*, 63(4), 479-488.
- Mehrotra, M., Wang, G., & Johnson, W. M. (2000). Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *Journal of Clinical Microbiology*, 38(3), 1032-1035.

- Omar, N. N., & Mohammed, R. K. (2021). A molecular study of toxic shock syndrome toxin gene (test-1) in β -lactam resistant *Staphylococcus aureus* clinical isolates. *Iraqi Journal of Science*, 825-837.
- Paraiso, M. F. R., Ferrando, C. A., Sokol, E. R., Rardin, C. R., Matthews, C. A., Karram, M. M., & Iglesia, C. B. (2020). A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. *Menopause*, 27(1), 50-56.
- Parsonnet, J., Hansmann, M. A., Delaney, M. L., Modern, P. A., DuBois, A. M., Wieland-Alter, W., Wissemann, K. W., Wild, J. E., Jones, M. B., & Seymour, J. L. (2005). Prevalence of toxic shock syndrome toxin 1-producing *Staphylococcus aureus* and the presence of antibodies to this superantigen in menstruating women. *Journal of Clinical Microbiology*, 43(9), 4628-4634.
- Pereira, S. R., Tello Velasquez, J., Duggan, S., Ivanisevic, B., McKenna, J. P., McCreary, C., & Downer, E. J. (2022). Recent advances in understanding the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids. *European Journal of Neuroscience*, 55(4), 1032-1050.
- Riyal, H., Samaranayake, N., Amarathunga, P., Munidasa, D., & Karunaweera, N. D. (2023). Histological findings associated with treatment response in cutaneous leishmaniasis: A clinicopathological correlation study. *International Journal of Dermatology*, 62(10), 1237-1247.
- Sánchez, S. V. G. (2020). *Efficacy of antimicrobial treatments against Salmonella enterica on pork and Campylobacter jejuni on poultry* [Colorado State University].
- Schlievert, P. M., Gaitán, A. V., Kilgore, S. H., Roe, A. L., Maukonen, J., Lehtoranta, L., Leung, D. Y., & Marsman, D. S. (2023). Inhibition of toxic shock syndrome-associated *Staphylococcus aureus* by probiotic lactobacilli. *Microbiology Spectrum*, 11(4), e01735-01723.
- Tikka, T., Kavanagh, K., Lowit, A., Jiafeng, P., Burns, H., Nixon, I. J., Paleri, V., & MacKenzie, K. (2020). Head and neck cancer risk calculator (HaNC-RC)—V. 2. Adjustments and addition of symptoms and social history factors. *Clinical Otolaryngology*, 45(3), 380-388.
- You, C., Wu, Z., Liao, M., Ye, X., Li, L., & Yang, T. (2023). Associated Outcomes of Different Intravenous Antibiotics Combined with 2% Mupirocin Ointment in the Treatment of Pediatric



Patients with Staphylococcal Scalded Skin Syndrome. *Clinical, Cosmetic and Investigational Dermatology*, 1691-1701.